Establish MAM to track the cause of color change in a protein therapeutic
Learn about the link between AGE formation and color change in final drug products. Explore how to develop assays that enable rapid monitoring and tracking of these post-translational modifications (PTMs).
Because a product quality attribute (PQA) may impact efficacy and safety, the color of a protein therapeutic under process development, and any changes to that color, require close monitoring.
Register now
This webinar discusses the use of a LC-MS workflow for detailed peptide mapping of PTMs to:
• Define potential PQAs associated with color change
• Investigate the link between color change and advanced glycan end products (AGEs)
• Characterize and localize AGEs linked to color change
• Establish a MAM to quantitatively track AGEs
Presented by:
Andrew D. Mahan PhD
Mass Spec group leader
Cell Engineering and Analytical Sciences
J&J Innovative Medicines